Riskpilot← Back to searchSign inGet full accessFagerström Pharma Systems AB
ABActiveOrg 5567146302La Cours Gata 4Engineering activities and related technical consultancy · NACE 7112Est. 20060 employees
Revenue 2025
SEK 0
EBITDA margin
—
+55% vs 2024
Equity ratio
100.0%
Financial strength
Net profit 2025
SEK 1K
0 employees
| Revenue | SEK 0 | — |
| EBITDA | SEK -5K | +55% |
| Net profit | SEK 1K | — |
| Total assets | SEK 242K | -2% |
| Equity | SEK 242K | +0% |
| Employees | 0 | — |
Legal name
Fagerström Pharma Systems AB
Org number
5567146302
Legal form
Aktiebolag
NACE code
7112 · Engineering activities and related technical consultancy
Founded
6 november 2006
Share capital
SEK 100 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2025-04-30
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Dessutom har verkställande direktören rätt att teckna firman beträffande löpande förvaltningsåtgärder
Company purpose
Bolaget skall bedriva teknisk konsultverksamhet inom sjukvårds- och läkemedelsindustrin samt därmed förenlig verksamhet.
Address
La Cours Gata 4
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Staff expenses | — | — | — | — | — |
| EBITDA | −10 | −10 | −10 | −11 | −5 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −0 |
| EBIT | −10 | −10 | −10 | −11 | −5 |
| Net financials | — | — | 1 | 8 | 6 |
| Profit before tax | 1 | 0 | 0 | 0 | 1 |
| Tax | −0 | −0 | −0 | −0 | −0 |
| Net profit | 1 | 0 | 0 | 0 | 1 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 247 | 247 | 247 | 247 | 242 |
| Equity | 241 | 241 | 241 | 241 | 242 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 6 | 6 | 6 | 6 | 0 |
| Total debt | 6 | 6 | 6 | 6 | — |
EBITDA margin
-500000.0%
This company
15.8%
Market median
-3164657% vs market
20212025
Equity ratio
100.0%
This company
38.2%
Market median
+162% vs market
20212025
Return on equity
0.4%
This company
18.4%
Market median
-98% vs market
20212025
Net profit margin
100000.0%
This company
8.1%
Market median
+1234468% vs market
20212025
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20212025
Debt / equity
0.00×
This company
0.62×
Market median
+100% vs market
20212025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2024-05-01 – 2025-04-30
- Annual report 2024Filed via Bolagsverket / SCB · Period 2023-05-01 – 2024-04-30
- Annual report 2023Filed via Bolagsverket / SCB · Period 2022-05-01 – 2023-04-30
- Annual report 2022Filed via Bolagsverket / SCB · Period 2021-05-01 – 2022-04-30
- Annual report 2021Filed via Bolagsverket / SCB · Period 2020-05-01 – 2021-04-30
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
CJ Chief Executive Officer | Chief Executive Officer | 2024 |
| Former (1) | ||
KM Audit | Audit | 2020 – 2024 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Deputy Board Member | 2020 | |
| Board of Directors | 2020 | |
| Former (1) | ||
| Chairman | 2020 – 2020 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 100% | 100% | 2023 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Fagerström Industrikonsult Aktiebolag
Fagerström Pharma Systems AB Board members of Fagerström Pharma Systems AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Kim Martin Lavin | Audit | 0 companies |
| Carl Johan Bernt Fagerström | Chief Executive Officer | 0 companies |
| Per Staffan Fagerström | Chairman | 0 companies |
| Ingrid Lena Christine Fagerström | Deputy Board Member | 0 companies |
| Nils Lennart Åström | Board of Directors | 0 companies |